Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets. 

Biotechnology

Assembly Biosciences

Jason Okazaki

Anuj Gaggar

Zhixin Z.

Suzette DeVito

Qi Huang

John O. Gunderson

Grace Wang

Gayan Bogollaga

Nicole S. White

William Delaney

Jennifer Troia

The Scientific Team at Assembly Biosciences is responsible for the discovery, development, and advancement of innovative core inhibitor drug candidates aimed at curing hepatitis B virus (HBV). This team of experts conducts cutting-edge research on HBV mechanisms, designs proof-of-concept studies, and identifies novel therapeutic targets to disrupt the viral replication cycle, thereby contributing to the company's mission of providing finite and curative HBV therapies.

Scientific Team

Directors and Senior Directors Team

Leadership Team

��

Scientific Team

About

Team members

Other teams at Assembly Biosciences

Directors and Senior Directors Team

Leadership Team

��������

Scientific Team

About

Team members

Other teams at Assembly Biosciences

Directors and Senior Directors Team

Leadership Team

��